JP Morgan Maintains Overweight on Amicus Therapeutics, Raises Price Target to $19
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Anupam Rama maintains an Overweight rating on Amicus Therapeutics (NASDAQ:FOLD) and raises the price target from $17 to $19.
September 29, 2023 | 11:25 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JP Morgan maintains an Overweight rating on Amicus Therapeutics and raises the price target from $17 to $19, indicating a positive outlook for the company.
The raised price target by JP Morgan indicates a positive outlook for Amicus Therapeutics. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100